Document Detail


Safety of specific immunotherapy: a retrospective study.
MedLine Citation:
PMID:  7874322     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A large experience in specific immunotherapy is reviewed in order to assess the safety of this treatment. From 1968 through September 30, 1993, 300,086 injections were administered to 6,319 patients suffering from allergic asthma and/or rhinitis. Systemic reactions reported during the whole period were 184 (0.061%) in 134 subjects (2.1%) and consisted of: urticaria (59.3%), mild asthmatic attacks (23.9%), asthma and urticaria (9.7%), and spasmodic rhinitis (7.1%). The absence of cases of anaphylaxis confirms the safety of specific immunotherapy. This kind of treatment should be considered as first-line therapy, if carried out in a specialized setting.
Authors:
A Luigi; G Senna; P Mezzelani; G Pappalardo
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of investigational allergology & clinical immunology     Volume:  4     ISSN:  1018-9068     ISO Abbreviation:  J Investig Allergol Clin Immunol     Publication Date:    1994 Sep-Oct
Date Detail:
Created Date:  1995-04-05     Completed Date:  1995-04-05     Revised Date:  2013-07-31    
Medline Journal Info:
Nlm Unique ID:  9107858     Medline TA:  J Investig Allergol Clin Immunol     Country:  SPAIN    
Other Details:
Languages:  eng     Pagination:  250-4     Citation Subset:  IM    
Affiliation:
Allergy Department of Verona General Hospital, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Asthma / therapy
Desensitization, Immunologic / adverse effects*
Female
Humans
Male
Respiratory Hypersensitivity / therapy*
Retrospective Studies
Rhinitis / therapy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Serum sickness due to bovine serum albumin sensitization during in vitro fertilization.
Next Document:  Suppression of IgA production by lymphocytes induced by diphenylhydantoin.